Novavax sells Czech facility to Novo Nordisk for $200 million

In a strategic transfer to streamline its operations, Novavax (NASDAQ:NVAX), a U.S. vaccine producer, has introduced the sale of its manufacturing plant within the Czech Republic to the Danish pharmaceutical firm Novo Nordisk (NYSE:NVO).

The transaction is valued at $200 million. Novavax plans to channel the funds from this sale into its vaccine improvement pipeline.

The corporate, identified for its work on COVID-19 vaccines, has confronted challenges competing with trade leaders like Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE). Issues have been raised final 12 months over Novavax’s monetary sustainability.

This sale is part of Novavax’s broader technique to reshape its enterprise construction. It follows a big licensing settlement with Sanofi (NASDAQ:SNY), a French pharmaceutical large. Underneath the deal, Sanofi took practically a 5% possession stake in Novavax in return for rights to its COVID-19 vaccine, amounting to not less than $1.2 billion.

Because the settlement with Sanofi in Could, Novavax’s inventory has seen a substantial upswing, with a rise of roughly 88%.

John Jacobs, Novavax’s Chief Govt Officer, emphasised the corporate’s dedication to turning into a extra environment friendly entity.

“The choice to promote the Czech Republic manufacturing facility aligns with our beforehand introduced dedication to evolve Novavax right into a extra lean and agile group targeted on partnering our pipeline belongings and expertise platform,” Jacobs acknowledged.

The sale is predicted to cut back Novavax’s annual working bills by round $80 million, aiding in its endeavor to streamline operations and deal with its core capabilities in vaccine improvement.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.